Login to Your Account

XOMA's IL-1 Inhibitor Down and Out in Type II Diabetes

By Catherine Shaffer

Thursday, March 24, 2011
XOMA Ltd.'s stock slid nearly 30 percent Wednesday on news that its investigational interleukin-1 inhibitor, XOMA 052, missed its primary endpoint in a Phase IIb trial in Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription